{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:50:24Z","timestamp":1788731424943,"version":"build-2803163510"},"reference-count":224,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biol Eng"],"DOI":"10.1186\/s13036-025-00534-8","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T13:42:04Z","timestamp":1753364524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeting rheumatoid arthritis: a molecular perspective on biologic therapies and clinical progress"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-1860","authenticated-orcid":false,"given":"Ankit","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Bishnoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-579X","authenticated-orcid":false,"given":"Shiv Kumar","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedha","family":"Kapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Singhvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinath","family":"Palakurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"3","key":"534_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/art.1780170302","volume":"17","author":"CL Short","year":"1974","unstructured":"Short CL. The antiquity of rheumatoid arthritis. Arthritis Rheum-Us. 1974;17(3):193\u2013205.","journal-title":"Arthritis Rheum-Us"},{"issue":"1","key":"534_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ph14010031","volume":"14","author":"N Das","year":"2020","unstructured":"Das N, Benko C, Gill SE, Dufour A. The Pharmacological TAILS of matrix metalloproteinases and their inhibitors. Pharmaceuticals. 2020;14(1):31.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"534_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hcl.2010.09.006","volume":"27","author":"P Entezami","year":"2011","unstructured":"Entezami P, Fox DA, Clapham PJ, Chung KC. Historical perspective on the etiology of rheumatoid arthritis. Hand Clin. 2011;27(1):1\u201310.","journal-title":"Hand Clin"},{"issue":"10","key":"534_CR4","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","volume":"5","author":"RJ Black","year":"2023","unstructured":"Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H, Kopec JA, Brooks PM, Woolf AD, Ong KL. Global, regional, and National burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol. 2023;5(10):e594\u2013610.","journal-title":"Lancet Rheumatol"},{"issue":"10086","key":"534_CR5","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328\u201337.","journal-title":"Lancet"},{"issue":"1","key":"534_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern Pharmacologic therapies. Bone Res. 2018;6(1):1\u201314.","journal-title":"Bone Res"},{"issue":"6","key":"534_CR7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.medici.2015.11.002","volume":"51","author":"L Akramas","year":"2015","unstructured":"Akramas L, Leonavi\u010dien\u0117 L, Vasiliauskas A, Brad\u016bnait\u0117 R, Vaitkien\u0117 D, Zabulyt\u0117 D, Normantien\u0117 T, Luko\u0161ius A, Jonauskien\u0117 I. Anti-inflammatory and anti-oxidative effects of herbal Preparation EM 1201 in adjuvant arthritic rats. Medicina. 2015;51(6):368\u201377.","journal-title":"Medicina"},{"key":"534_CR8","doi-asserted-by":"crossref","unstructured":"Brown P, Pratt AG, Hyrich KL. Therapeutic advances in rheumatoid arthritis. BMJ 2024, 384.","DOI":"10.1136\/bmj-2022-070856"},{"issue":"3","key":"534_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jtcms.2016.02.004","volume":"2","author":"PS Kothavade","year":"2015","unstructured":"Kothavade PS, Bulani VD, Deshpande PS, Chowdhury AS, Juvekar AR. The petroleum ether fraction of Celastrus paniculatus willd. Seeds demonstrates anti-arthritic effect in adjuvant-induced arthritis in rats. J Traditional Chin Med Sci. 2015;2(3):183\u201393.","journal-title":"J Traditional Chin Med Sci"},{"issue":"5","key":"534_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1759720X10378372","volume":"2","author":"S Srirangan","year":"2010","unstructured":"Srirangan S, Choy EH. The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(5):247\u201356.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"534_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42358-018-0042-8","volume":"59","author":"S de Brito Rocha","year":"2019","unstructured":"de Brito Rocha S, Baldo DC, Andrade LEC. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol. 2019;59(1):2.","journal-title":"Adv Rheumatol"},{"key":"534_CR12","doi-asserted-by":"crossref","unstructured":"Derksen V, Huizinga T, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. In: Semin immunopathol: 2017: Springer; 2017: 437\u201346.","DOI":"10.1007\/s00281-017-0627-z"},{"issue":"3","key":"534_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ddmec.2004.10.006","volume":"1","author":"PC Taylor","year":"2004","unstructured":"Taylor PC, Feldmann M. Rheumatoid arthritis: pathogenic mechanisms and therapeutic targets. Drug Discov Today Dis Mech. 2004;1(3):289\u201395.","journal-title":"Drug Discov Today Dis Mech"},{"issue":"9","key":"534_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3109\/1061186X.2014.928714","volume":"22","author":"M Bishnoi","year":"2014","unstructured":"Bishnoi M, Jain A, Hurkat P, Jain SK. Aceclofenac-loaded chondroitin sulfate conjugated SLNs for effective management of osteoarthritis. J Drug Target. 2014;22(9):805\u201312.","journal-title":"J Drug Target"},{"issue":"5","key":"534_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10719-016-9665-3","volume":"33","author":"M Bishnoi","year":"2016","unstructured":"Bishnoi M, Jain A, Hurkat P, Jain SK. Chondroitin sulphate: a focus on osteoarthritis. Glycoconj J. 2016;33(5):693\u2013705.","journal-title":"Glycoconj J"},{"key":"534_CR16","doi-asserted-by":"crossref","unstructured":"Bishnoi M, Jain A, Singla Y, Shrivastava B. Sublingual delivery of chondroitin sulfate conjugated tapentadol loaded nanovesicles for the treatment of osteoarthritis. J Liposome Res 2020:1\u201315.","DOI":"10.1080\/08982104.2020.1730400"},{"issue":"6","key":"534_CR17","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3390\/ijms20061332","volume":"20","author":"S-J Chen","year":"2019","unstructured":"Chen S-J, Lin G-J, Chen J-W, Wang K-C, Tien C-H, Hu C-F, Chang C-N, Hsu W-F, Fan H-C, Sytwu H-K. Immunopathogenic mechanisms and novel immune-modulated therapies in rheumatoid arthritis. Int J Mol Sci. 2019;20(6):1332.","journal-title":"Int J Mol Sci"},{"key":"534_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.intimp.2018.11.034","volume":"66","author":"K Langdon","year":"2019","unstructured":"Langdon K, Phie J, Thapa CB, Biros E, Loukas A, Haleagrahara N. Helminth-based therapies for rheumatoid arthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2019;66:366\u201372.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"534_CR19","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.1002\/jcp.27860","volume":"234","author":"M Abbasi","year":"2019","unstructured":"Abbasi M, Mousavi MJ, Jamalzehi S, Alimohammadi R, Bezvan MH, Mohammadi H, Aslani S. Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2019;234(7):10018\u201331.","journal-title":"J Cell Physiol"},{"issue":"1","key":"534_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/BOR.0000000000000664","volume":"32","author":"F Coutant","year":"2020","unstructured":"Coutant F, Miossec P. Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. Curr Opin Rheumatol. 2020;32(1):57\u201363.","journal-title":"Curr Opin Rheumatol"},{"key":"534_CR21","doi-asserted-by":"publisher","first-page":"3830212","DOI":"10.1155\/2020\/3830212","volume":"2020","author":"Q Fang","year":"2020","unstructured":"Fang Q, Zhou C, Nandakumar KS. Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis. Mediators Inflamm. 2020;2020:3830212.","journal-title":"Mediators Inflamm"},{"issue":"suppl5","key":"534_CR22","doi-asserted-by":"publisher","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","volume":"51","author":"E Choy","year":"2012","unstructured":"Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012;51(suppl5):v3\u201311.","journal-title":"Rheumatology"},{"issue":"1","key":"534_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/1529-0131(200102)45:1<101::AID-ANR90>3.0.CO;2-7","volume":"45","author":"WP Arend","year":"2001","unstructured":"Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Care Research: Official J Am Coll Rheumatol. 2001;45(1):101\u20136.","journal-title":"Arthritis Care Research: Official J Am Coll Rheumatol"},{"issue":"11","key":"534_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/intimm\/dxr077","volume":"23","author":"T Mori","year":"2011","unstructured":"Mori T, Miyamoto T, Yoshida H, Asakawa M, Kawasumi M, Kobayashi T, Morioka H, Chiba K, Toyama Y, Yoshimura A. IL-1\u03b2 and TNF\u03b1-initiated IL-6\u2013STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol. 2011;23(11):701\u201312.","journal-title":"Int Immunol"},{"key":"534_CR25","doi-asserted-by":"crossref","unstructured":"Harre U, Schett G. Cellular and molecular pathways of structural damage in rheumatoid arthritis. In: Semin immunopathol: 2017: Springer; 2017: 355\u201363.","DOI":"10.1007\/s00281-017-0634-0"},{"issue":"1","key":"534_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12896-023-00776-8","volume":"23","author":"Y Qin","year":"2023","unstructured":"Qin Y, Wu G, Jin J, Wang H, Zhang J, Liu L, Zhao H, Wang J, Yang X. A fully human connective tissue growth factor blocking monoclonal antibody ameliorates experimental rheumatoid arthritis through inhibiting angiogenesis. BMC Biotechnol. 2023;23(1):6.","journal-title":"BMC Biotechnol"},{"issue":"4","key":"534_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tips.2015.02.001","volume":"36","author":"MI Koenders","year":"2015","unstructured":"Koenders MI, van den Berg WB. Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol Sci. 2015;36(4):189\u201395.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"534_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","volume":"33","author":"ATV Haikarainen","year":"2019","unstructured":"Haikarainen ATV, Raivola T, Silvennoinen J. Selective jakinibs: prospects in inflammatory and autoimmune diseases. Biodrugs. 2019;33(1):15\u201332.","journal-title":"Biodrugs"},{"issue":"1","key":"534_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12964-019-0356-0","volume":"17","author":"H Reeh","year":"2019","unstructured":"Reeh H, Rudolph N, Billing U, Christen H, Streif S, Bullinger E, Schliemann-Bullinger M, Findeisen R, Schaper F, Huber HJ, et al. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor \u03b1 to gp130 expression: fusing experimental insights and dynamic modelling. Cell Communication Signal. 2019;17(1):46.","journal-title":"Cell Communication Signal"},{"issue":"4","key":"534_CR30","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1186\/ar2772","volume":"11","author":"EM Moran","year":"2009","unstructured":"Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, FitzGerald O, Bresnihan B, Veale DJ, Fearon U. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-\u03b1, Oncostatin M and response to biologic therapies. Arthritis Res Therapy. 2009;11(4):R113.","journal-title":"Arthritis Res Therapy"},{"key":"534_CR31","first-page":"5407","volume":"10","author":"K Roy","year":"2015","unstructured":"Roy K, Kanwar RK, Kanwar JR. Molecular targets in arthritis and recent trends in nanotherapy. Int J Nanomed. 2015;10:5407\u201320.","journal-title":"Int J Nanomed"},{"key":"534_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaut.2017.12.006","volume":"87","author":"JP van Hamburg","year":"2018","unstructured":"van Hamburg JP, Tas SW. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis. J Autoimmun. 2018;87:69\u201381.","journal-title":"J Autoimmun"},{"key":"534_CR33","doi-asserted-by":"crossref","unstructured":"Crotti C, Agape E, Becciolini A, Biggioggero M, Favalli EG. Targeting granulocyte-monocyte colony-stimulating factor signaling in rheumatoid arthritis: future prospects. Drugs 2019:1\u201315.","DOI":"10.1007\/s40265-019-01192-z"},{"key":"534_CR34","doi-asserted-by":"crossref","unstructured":"Hamilton JA. GM-CSF in inflammation. J Exp Med 2020, 217(1).","DOI":"10.1084\/jem.20190945"},{"key":"534_CR35","doi-asserted-by":"crossref","unstructured":"Bykerk VP. The efficacy and safety of targeting GM-CSF in arthritis. Lancet Rheumatol 2020.","DOI":"10.1016\/S2665-9913(20)30352-0"},{"issue":"4","key":"534_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/rheumatology\/kem297","volume":"47","author":"T Thalhamer","year":"2008","unstructured":"Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology. 2008;47(4):409\u201314.","journal-title":"Rheumatology"},{"issue":"7","key":"534_CR37","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2007.074278","volume":"67","author":"G Schett","year":"2008","unstructured":"Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):909\u201316.","journal-title":"Ann Rheum Dis"},{"key":"534_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4172\/2155-9899.1000160","volume":"4","author":"CJ Malemud","year":"2013","unstructured":"Malemud CJ. Intracellular signaling pathways in rheumatoid arthritis. J Clin Cell Immunol. 2013;4:160.","journal-title":"J Clin Cell Immunol"},{"key":"534_CR39","doi-asserted-by":"crossref","unstructured":"Weichhart T, emann S M D, editors. 2008. The PI3K\/Akt\/mTOR pathway in innate immune cells: Emerging therapeutic applications. Ann Rheum Dis, 67.","DOI":"10.1136\/ard.2008.098459"},{"issue":"9","key":"534_CR40","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.4155\/fmc.15.55","volume":"7","author":"CJ Malemud","year":"2015","unstructured":"Malemud CJ. The PI3K\/Akt\/PTEN\/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? Future Med Chem. 2015;7(9):1137\u201347.","journal-title":"Future Med Chem"},{"key":"534_CR41","doi-asserted-by":"crossref","unstructured":"Liu K, Zhang Y, Liu L, Yuan Q. miR-125 regulates PI3K\/Akt\/mTOR signaling pathway in rheumatoid arthritis rats via PARP2. Biosci Rep 2019, 39(1).","DOI":"10.1042\/BSR20180890"},{"key":"534_CR42","doi-asserted-by":"crossref","unstructured":"Cheung TT, McInnes IB. Future therapeutic targets in rheumatoid arthritis? In: Semin immunopathol: 2017: Springer; 2017: 487\u2013500.","DOI":"10.1007\/s00281-017-0623-3"},{"issue":"1","key":"534_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13075-016-0988-z","volume":"18","author":"JK Park","year":"2016","unstructured":"Park JK, Byun J-Y, Park JA, Kim Y-Y, Lee YJ, Oh JI, Jang SY, Kim YH, Song YW, Son J. HM71224, a novel bruton\u2019s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Res Therapy. 2016;18(1):91.","journal-title":"Arthritis Res Therapy"},{"key":"534_CR44","doi-asserted-by":"crossref","unstructured":"Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R. Discovery of GDC-0853: a potent, selective, and noncovalent bruton\u2019s tyrosine kinase inhibitor in early clinical development. In.: ACS; 2018.","DOI":"10.1021\/acs.jmedchem.7b01712"},{"issue":"4","key":"534_CR45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4155\/tde-2020-0029","volume":"11","author":"S Gorantla","year":"2020","unstructured":"Gorantla S, Singhvi G, Rapalli VK, Waghule T, Dubey SK, Saha RN. Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status. Ther Deliv. 2020;11(4):269\u201384.","journal-title":"Ther Deliv"},{"issue":"2","key":"534_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.autrev.2009.03.010","volume":"9","author":"L Senolt","year":"2009","unstructured":"Senolt L, Vencovsky J, Pavelka K, Ospelt C, Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev. 2009;9(2):102\u20137.","journal-title":"Autoimmun Rev"},{"key":"534_CR47","doi-asserted-by":"crossref","unstructured":"Ho RJ, Chien JY. Drug Delivery Trends in Clinical Trials and Translational Medicine: Growth in Biologic Molecule Development and Impact on Rheumatoid Arthritis, Crohn\u2019s Disease, and Colitis. J Pharm Sci 101: 2668\u20132674. J Pharm Sci 2012, 101(11):4365\u20134366.","DOI":"10.1002\/jps.23281"},{"issue":"7","key":"534_CR48","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/ard.2006.068304","volume":"66","author":"DE Furst","year":"2007","unstructured":"Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to Infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66(7):893\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"534_CR49","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s10067-015-3026-7","volume":"34","author":"N Berghen","year":"2015","unstructured":"Berghen N, Teuwen L-A, Westhovens R, Verschueren P. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study. Clin Rheumatol. 2015;34(10):1687\u201395.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"534_CR50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","volume":"74","author":"VP Bykerk","year":"2015","unstructured":"Bykerk VP, Cush J, Winthrop K, Calabrese L, Lortholary O, De Longueville M, Van Vollenhoven R, Mariette X. Update on the safety profile of certolizumab Pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74(1):96\u2013103.","journal-title":"Ann Rheum Dis"},{"key":"534_CR51","unstructured":"Gerriets V, Bansal P, Khaddour K. Tumor necrosis factor (TNF) inhibitors. StatPearls [Internet]. edn.: StatPearls Publishing; 2019."},{"issue":"12","key":"534_CR52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11926-018-0799-0","volume":"20","author":"L Chadwick","year":"2018","unstructured":"Chadwick L, Zhao S, Mysler E, Moots RJ. Review of biosimilar trials and data on etanercept in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(12):84.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"534_CR53","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/14737167.2019.1647104","volume":"19","author":"Z Zrubka","year":"2019","unstructured":"Zrubka Z, Gulacsi L, Brodszky V, Rencz F, Alten R, Szekanecz Z, Pentek M. Long-term efficacy and cost-effectiveness of Infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2019;19(5):537\u201349.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"534_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven Rv, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: a multicenter, randomized, double\u2010blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheumatism: Official J Am Coll Rheumatol. 2006;54(1):26\u201337.","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"3","key":"534_CR55","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/s10165-008-0045-0","volume":"18","author":"N Miyasaka","year":"2008","unstructured":"Miyasaka N, Investigators CS. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18(3):252\u201362.","journal-title":"Mod Rheumatol"},{"issue":"10","key":"534_CR56","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s12325-018-0757-2","volume":"35","author":"P Emery","year":"2018","unstructured":"Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S, Kola B. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv Ther. 2018;35(10):1535\u201363.","journal-title":"Adv Ther"},{"issue":"3","key":"534_CR57","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/jcm8030387","volume":"8","author":"E Pelechas","year":"2019","unstructured":"Pelechas E, Voulgari PV, Drosos AA. Golimumab for rheumatoid arthritis. J Clin Med. 2019;8(3):387.","journal-title":"J Clin Med"},{"key":"534_CR58","doi-asserted-by":"crossref","unstructured":"Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Reviews 2010(1).","DOI":"10.1002\/14651858.CD008341"},{"issue":"12","key":"534_CR59","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1517\/14712598.2012.732062","volume":"12","author":"JR Nair","year":"2012","unstructured":"Nair JR, Edwards SW, Moots RJ. Mavrilimumab, a human monoclonal GM-CSF receptor-alpha antibody for the management of rheumatoid arthritis: a novel approach to therapy. Expert Opin Biol Ther. 2012;12(12):1661\u20138.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"534_CR60","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.bjc.6605816","volume":"103","author":"MC Ryan","year":"2010","unstructured":"Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, Kim KM, Nesterova A, Anderson M, McEarchern JA, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010;103(5):676\u201384.","journal-title":"Br J Cancer"},{"key":"534_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/DDDT.S104233","volume":"11","author":"C Crotti","year":"2017","unstructured":"Crotti C, Raimondo MG, Becciolini A, Biggioggero M, Favalli EG. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther. 2017;11:211.","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"534_CR62","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1136\/ard.2010.146225","volume":"70","author":"GR Burmester","year":"2011","unstructured":"Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-\u03b1, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis. 2011;70(9):1542\u20139.","journal-title":"Ann Rheum Dis"},{"key":"534_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/CE.S39770","volume":"9","author":"M Di Franco","year":"2014","unstructured":"Di Franco M, Gerardi MC, Lucchino B, Conti F. Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis. Core Evid. 2014;9:41\u20138.","journal-title":"Core Evid"},{"issue":"6","key":"534_CR64","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/annrheumdis-2013-204816","volume":"74","author":"F Behrens","year":"2015","unstructured":"Behrens F, Tak PP, \u00d8stergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A. MOR103, a human monoclonal antibody to granulocyte\u2013macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase ib\/iia randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015;74(6):1058\u201364.","journal-title":"Ann Rheum Dis"},{"key":"534_CR65","doi-asserted-by":"crossref","unstructured":"Onuora S. Namilumab improves RA symptoms. In. Nature Publishing Group; 2019.","DOI":"10.1038\/s41584-019-0231-9"},{"issue":"1","key":"534_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1879-x","volume":"21","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T, Matsievskaia G, Hunt B, Wagner T, Souberbielle B. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Res Therapy. 2019;21(1):1\u201313.","journal-title":"Arthritis Res Therapy"},{"key":"534_CR67","doi-asserted-by":"crossref","unstructured":"Kivitz A, Hazan L, Hoffman K, Wallin B. FRI0209 MORAb-022, an anti-granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody (MAB): results of the first study in patients with mild-to-moderate rheumatoid arthritis (RA). In.: BMJ Publishing Group Ltd; 2016.","DOI":"10.1136\/annrheumdis-2016-eular.3186"},{"key":"534_CR68","doi-asserted-by":"crossref","unstructured":"Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Research 2019, 8.","DOI":"10.12688\/f1000research.18688.1"},{"issue":"Pt 2","key":"534_CR69","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/bj3340297","volume":"334","author":"PC Heinrich","year":"1998","unstructured":"Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway. Biochem J. 1998;334(Pt 2):297\u2013314.","journal-title":"Biochem J"},{"issue":"1\u20132","key":"534_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0161-5890(00)00018-3","volume":"37","author":"K Imada","year":"2000","unstructured":"Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37(1\u20132):1\u201311.","journal-title":"Mol Immunol"},{"key":"534_CR71","doi-asserted-by":"crossref","unstructured":"Schindler C, Plumlee C. Inteferons pen the JAK\u2013STAT pathway. In: Semin Cell Dev Biol: 2008: Elsevier; 2008: 311\u2013318.","DOI":"10.1016\/j.semcdb.2008.08.010"},{"issue":"13","key":"534_CR72","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"534_CR73","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13075-017-1410-1","volume":"19","author":"M Schiff","year":"2017","unstructured":"Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, Kuo W-L, Won J-E, Carmack T, Rooney T. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Therapy. 2017;19(1):208.","journal-title":"Arthritis Res Therapy"},{"key":"534_CR74","doi-asserted-by":"crossref","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, Van Vollenhoven R. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","DOI":"10.1136\/annrheumdis-2016-210715"},{"issue":"7","key":"534_CR75","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362.","journal-title":"N Engl J Med"},{"issue":"6","key":"534_CR76","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Baricitinib: first global approval. Drugs. 2017;77(6):697\u2013704.","journal-title":"Drugs"},{"key":"534_CR77","doi-asserted-by":"crossref","unstructured":"Zamora NV, Tayar JH, Lopez-Olivo MA, Christensen R, Suarez\u2010Almazor ME. Baricitinib for rheumatoid arthritis. Cochrane Database Syst Reviews 2019(4).","DOI":"10.1002\/14651858.CD013311"},{"issue":"5","key":"534_CR78","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40259-016-0190-5","volume":"30","author":"S Nakayamada","year":"2016","unstructured":"Nakayamada S, Kubo S, Iwata S, Tanaka Y. Recent progress in JAK inhibitors for the treatment of rheumatoid arthritis. BioDrugs. 2016;30(5):407\u201319.","journal-title":"BioDrugs"},{"issue":"8","key":"534_CR79","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40265-019-01131-y","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ. Peficitinib: first global approval. Drugs. 2019;79(8):887\u201391.","journal-title":"Drugs"},{"issue":"Supplement1","key":"534_CR80","doi-asserted-by":"publisher","first-page":"S497","DOI":"10.1093\/ecco-jcc\/jjz203.725","volume":"14","author":"R Besuyen","year":"2020","unstructured":"Besuyen R, Walker D, Winthrop K, Genovese M, Combe B, Tanaka Y, Kivitz A, Matzkies F, Bartok B, Ye L. P597 pooled safety analyses from phase 3 studies of filgotinib in patients with rheumatoid arthritis. J Crohn\u2019s Colitis. 2020;14(Supplement1):S497\u20138.","journal-title":"J Crohn\u2019s Colitis"},{"key":"534_CR81","doi-asserted-by":"crossref","unstructured":"oth LJM, Szabo L, Abada A, Kiss F, Hegyi P et al. Janus kinase inhibitors improve disease activity and Patient-Reported outcomes in rheumatoid arthritis: A systematic review and Meta-Analysis of 24,135 patients. Int J Mol Sci 2022;23(3).","DOI":"10.3390\/ijms23031246"},{"key":"534_CR82","doi-asserted-by":"publisher","first-page":"106577","DOI":"10.1016\/j.bioorg.2023.106577","volume":"138","author":"L Wang","year":"2023","unstructured":"Wang L, Zhang Z, Yu D, Yang L, Li L, He Y, Shi J. Recent research of BTK inhibitors: methods of structural design, Pharmacological activities, manmade derivatives and structure-activity relationship. Bioorg Chem. 2023;138:106577.","journal-title":"Bioorg Chem"},{"issue":"1","key":"534_CR83","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nchembio.481","volume":"7","author":"JA Di Paolo","year":"2011","unstructured":"Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, et al. Specific Btk Inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7(1):41\u201350.","journal-title":"Nat Chem Biol"},{"issue":"2","key":"534_CR84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.13172\/2052-9554-1-2-1120","volume":"1","author":"A Chu","year":"2013","unstructured":"Chu A, Chang B. B-cell kinase inhibitors in rheumatoid arthritis. OA Arthritis. 2013;1(2):17.","journal-title":"OA Arthritis"},{"issue":"23","key":"534_CR85","doi-asserted-by":"publisher","first-page":"7411","DOI":"10.3390\/molecules26237411","volume":"26","author":"B Tasso","year":"2021","unstructured":"Tasso B, Spallarossa A, Russo E, Brullo C. The development of BTK inhibitors: A Five-Year update. Molecules. 2021;26(23):7411.","journal-title":"Molecules"},{"issue":"8","key":"534_CR86","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/13543784.2016.1182499","volume":"25","author":"P Norman","year":"2016","unstructured":"Norman P. Investigational bruton\u2019s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2016;25(8):891\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"534_CR87","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1756-8722-6-59","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6(1):59.","journal-title":"J Hematol Oncol"},{"key":"534_CR88","doi-asserted-by":"crossref","unstructured":"Ringheim GE, Wampole M, Oberoi K. Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol 2021, Volume 12\u20132021.","DOI":"10.3389\/fimmu.2021.662223"},{"key":"534_CR89","doi-asserted-by":"crossref","unstructured":"De Bondt M, Renders J, Struyf S, Hellings N. Inhibitors of Bruton\u2019s tyrosine kinase as emerging therapeutic strategy in autoimmune diseases. Autoimmun Rev 2024:103532.","DOI":"10.1016\/j.autrev.2024.103532"},{"issue":"1","key":"534_CR90","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80.","journal-title":"J Hematol Oncol"},{"key":"534_CR91","doi-asserted-by":"crossref","unstructured":"Taylor PC, Schett G, Huizinga TW, Wang Q, Ibrahim F, Zhou B, Liva SG, Shaik JSB, Xiong Y, Leu JH et al. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open 2024, 10(2).","DOI":"10.1136\/rmdopen-2024-004278"},{"issue":"2","key":"534_CR92","doi-asserted-by":"publisher","first-page":"e0282117","DOI":"10.1371\/journal.pone.0282117","volume":"18","author":"D Akasaka","year":"2023","unstructured":"Akasaka D, Iguchi S, Kaneko R, Yoshiga Y, Kajiwara D, Nakachi Y, Noma N, Tanaka K, Shimizu A, Hosoi F. Novel bruton\u2019s tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis. PLoS ONE. 2023;18(2):e0282117.","journal-title":"PLoS ONE"},{"issue":"12","key":"534_CR93","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1002\/art.10623","volume":"46","author":"E Choy","year":"2002","unstructured":"Choy E, Isenberg D, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R. Therapeutic benefit of blocking interleukin-6 activity with an anti\u2013interleukin\u20106 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double\u2010blind, placebo\u2010controlled, dose\u2010escalation trial. Arthr Rhuem. 2002;46(12):3143\u201350.","journal-title":"Arthr Rhuem"},{"issue":"1","key":"534_CR94","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","volume":"19","author":"N Nishimoto","year":"2009","unstructured":"Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Study of active controlled Tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor Inhibition therapy. Mod Rheumatol. 2009;19(1):12\u20139.","journal-title":"Mod Rheumatol"},{"issue":"01","key":"534_CR95","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tom\u0161i\u010d M, Alecock E, Woodworth T. Comparison of Tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(01):88\u201396.","journal-title":"Ann Rheum Dis"},{"key":"534_CR96","first-page":"CMAMD","volume":"5","author":"A Ogata","year":"2012","unstructured":"Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of Tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights: Arthritis Musculoskelet Disorders. 2012;5:CMAMD.","journal-title":"Clin Med Insights: Arthritis Musculoskelet Disorders"},{"issue":"10042","key":"534_CR97","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","volume":"388","author":"JW Bijlsma","year":"2016","unstructured":"Bijlsma JW, Welsing PM, Woodworth TG, Middelink LM, Peth\u00f6-Schramm A, Bernasconi C, Borm ME, Wortel CH, Ter Borg EJ, Jahangier ZN. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016;388(10042):343\u201355.","journal-title":"Lancet"},{"issue":"9877","key":"534_CR98","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541\u201350.","journal-title":"Lancet"},{"issue":"9","key":"534_CR99","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TW Huizinga","year":"2014","unstructured":"Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part A trial. Ann Rheum Dis. 2014;73(9):1626\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"534_CR100","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.39944","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR. Sarilumab and nonbiologic Disease-Modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277\u201390.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"534_CR101","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/1744666X.2017.1351297","volume":"13","author":"AM Aly","year":"2017","unstructured":"Aly AM, Furst DE. Update of sarilumb to treat rheumatoid arthritis based on randomized clinical trials: a systematic review. Expert Rev Clin Immunol. 2017;13(8):741\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"534_CR102","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R, Van Adelsberg J, Mangan EK, Graham NM, Van Hoogstraten H, Bauer D, Vargas JI, Lee EB. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76(5):840\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"534_CR103","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73(9):1616\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"534_CR104","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","volume":"73","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C. Efficacy and safety of Olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study. Ann Rheum Dis. 2014;73(9):1607\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"534_CR105","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","volume":"81","author":"E Nasonov","year":"2022","unstructured":"Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG, Maslyanskiy AL, Samsonov M, Stoilov R, Zonova EV, et al. Olokizumab, a monoclonal antibody against Interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(4):469\u201379.","journal-title":"Ann Rheum Dis"},{"key":"534_CR106","doi-asserted-by":"crossref","unstructured":"D\u00f6rner T, Weinblatt M, Van Beneden K, Dombrecht E, De Beuf K, Schoen P, Zeldin RK. FRI0239 results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. In.: BMJ Publishing Group Ltd; 2017.","DOI":"10.1136\/annrheumdis-2017-eular.3746"},{"key":"534_CR107","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/ard.2003.016014","volume":"63","author":"S Cohen","year":"2004","unstructured":"Cohen S. 990145 study group. A multicentre, double blind, randomised, placebo controlled trial of Anakinra (Kineret), a Recombinant Interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63:1062\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"534_CR108","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.20221","volume":"50","author":"MC Genovese","year":"2004","unstructured":"Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P, Study G. Combination therapy with etanercept and Anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum-Us. 2004;50(5):1412\u20139.","journal-title":"Arthritis Rheum-Us"},{"issue":"1","key":"534_CR109","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and Anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"534_CR110","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","volume":"36","author":"S Kunwar","year":"2016","unstructured":"Kunwar S, Dahal K, Sharma S. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatol Int. 2016;36(8):1065\u201375.","journal-title":"Rheumatol Int"},{"key":"534_CR111","doi-asserted-by":"crossref","unstructured":"Jiang P, Wei K, Zhao J, Jin Y, Chang C, Zhang R, Xu L, Xu L, Shi Y, Guo S. Trends of Treatment Development in Rheumatoid Arthritis: Promise, Progress, and Challenges. 2022.","DOI":"10.20944\/preprints202203.0071.v2"},{"key":"534_CR112","doi-asserted-by":"publisher","first-page":"115666","DOI":"10.1016\/j.biopha.2023.115666","volume":"168","author":"Y Qin","year":"2023","unstructured":"Qin Y, Jin J, Zhang J, Wang H, Liu L, Zhang Y, Ling S, Hu J, Li N, Wang J, et al. A fully human monoclonal antibody targeting semaphorin 5A alleviates the progression of rheumatoid arthritis. Biomed Pharmacother. 2023;168:115666.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"534_CR113","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/TP.0b013e3182a860de","volume":"97","author":"BR Rosborough","year":"2014","unstructured":"Rosborough BR, Ra\u00efch-Regu\u00e9 D, Turnquist HR, Thomson AW. Regulatory myeloid cells in transplantation. Transplantation. 2014;97(4):367.","journal-title":"Transplantation"},{"issue":"6","key":"534_CR114","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.autrev.2015.01.014","volume":"14","author":"K Schinnerling","year":"2015","unstructured":"Schinnerling K, Soto L, Garcia-Gonzalez P, Catalan D, Aguillon JC. Skewing dendritic cell differentiation towards a tolerogenic state for recovery of tolerance in rheumatoid arthritis. Autoimmun Rev. 2015;14(6):517\u201327.","journal-title":"Autoimmun Rev"},{"issue":"290","key":"534_CR115","doi-asserted-by":"publisher","first-page":"ra290287","DOI":"10.1126\/scitranslmed.aaa9301","volume":"7","author":"H Benham","year":"2015","unstructured":"Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, Pahau H, Lee BT, Ng J, Brunck ME. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype\u2013positive rheumatoid arthritis patients. Sci Transl Med. 2015;7(290):ra290287\u2013290287.","journal-title":"Sci Transl Med"},{"issue":"6","key":"534_CR116","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1007\/s13346-021-01038-w","volume":"11","author":"AB Tu","year":"2021","unstructured":"Tu AB, Lewis JS. Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis. Drug Delivery Translational Res. 2021;11(6):2371\u201393.","journal-title":"Drug Delivery Translational Res"},{"issue":"4","key":"534_CR117","doi-asserted-by":"publisher","first-page":"105164","DOI":"10.1016\/j.jbspin.2021.105164","volume":"88","author":"A Page","year":"2021","unstructured":"Page A, Fusil F, Cosset F-L. Antigen-specific tolerance approach for rheumatoid arthritis: past, present and future. Joint Bone Spine. 2021;88(4):105164.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"534_CR118","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/blood-2008-04-150789","volume":"113","author":"W Xia","year":"2009","unstructured":"Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood. 2009;113(2):438\u201346.","journal-title":"Blood"},{"issue":"2","key":"534_CR119","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1515\/pterid-2015-0005","volume":"26","author":"G Jansen","year":"2015","unstructured":"Jansen G, Peters GJ. Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer. Pteridines. 2015;26(2):41\u201353.","journal-title":"Pteridines"},{"issue":"1","key":"534_CR120","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3109\/03639045.2015.1036066","volume":"42","author":"A Jain","year":"2016","unstructured":"Jain A, Jain SK. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer. Drug Dev Ind Pharm. 2016;42(1):136\u201349.","journal-title":"Drug Dev Ind Pharm"},{"issue":"7","key":"534_CR121","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2174\/1566524015666150831131320","volume":"15","author":"A Jain","year":"2015","unstructured":"Jain A, Jain SK. Colon targeted liposomal systems (CTLS): theranostic potential. Curr Mol Med. 2015;15(7):621\u201333.","journal-title":"Curr Mol Med"},{"issue":"8","key":"534_CR122","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11095-019-2653-0","volume":"36","author":"A Verma","year":"2019","unstructured":"Verma A, Jain A, Tiwari A, Saraf S, Panda PK, Agrawal GP, Jain SK. Folate conjugated double liposomes bearing prednisolone and methotrexate for targeting rheumatoid arthritis. Pharm Res. 2019;36(8):123.","journal-title":"Pharm Res"},{"issue":"4","key":"534_CR123","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/art.10871","volume":"48","author":"AB Blom","year":"2003","unstructured":"Blom AB, Radstake TR, Holthuysen AE, Sl\u00f6etjes AW, Pesman GJ, Sweep FG, van de Loo FA, Joosten L, Barrera P, van Lent PL. Increased expression of Fc\u03b3 receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor \u03b1 and matrix metalloproteinase. Arthritis Rheumatism: Official J Am Coll Rheumatol. 2003;48(4):1002\u201314.","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"9","key":"534_CR124","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/art.21228","volume":"52","author":"R Nagayoshi","year":"2005","unstructured":"Nagayoshi R, Nagai T, Matsushita K, Sato K, Sunahara N, Matsuda T, Nakamura T, Komiya S, Onda M, Matsuyama T. Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum-Us. 2005;52(9):2666\u201375.","journal-title":"Arthritis Rheum-Us"},{"issue":"3","key":"534_CR125","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/ar1944","volume":"8","author":"CM Paulos","year":"2006","unstructured":"Paulos CM, Varghese B, Widmer WR, Breur GJ, Vlashi E, Low PS. Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res Ther. 2006;8(3):R77.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"534_CR126","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1021\/mp900070b","volume":"6","author":"YS Yi","year":"2009","unstructured":"Yi YS, Ayala-Lopez W, Kularatne SA, Low PS. Folate-targeted Hapten immunotherapy of adjuvant-induced arthritis: comparison of Hapten potencies. Mol Pharm. 2009;6(4):1228\u201336.","journal-title":"Mol Pharm"},{"issue":"2","key":"534_CR127","doi-asserted-by":"publisher","first-page":"R37","DOI":"10.1186\/ar4191","volume":"15","author":"YY Gent","year":"2013","unstructured":"Gent YY, Weijers K, Molthoff CF, Windhorst AD, Huisman MC, Smith DE, Kularatne SA, Jansen G, Low PS, Lammertsma AA. Evaluation of the novel folate receptor ligand [18 F] fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res Therapy. 2013;15(2):R37.","journal-title":"Arthritis Res Therapy"},{"issue":"1","key":"534_CR128","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbrc.2007.06.054","volume":"360","author":"S Lee","year":"2007","unstructured":"Lee S, Murthy N. Targeted delivery of catalase and superoxide dismutase to macrophages using folate. Biochem Biophys Res Commun. 2007;360(1):275\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"534_CR129","doi-asserted-by":"publisher","first-page":"R59","DOI":"10.1186\/ar3312","volume":"13","author":"Y Feng","year":"2011","unstructured":"Feng Y, Shen J, Streaker ED, Lockwood M, Zhu Z, Low PS, Dimitrov DS. A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res Ther. 2011;13(2):R59.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"534_CR130","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1124\/jpet.111.185884","volume":"340","author":"Y Komano","year":"2012","unstructured":"Komano Y, Yagi N, Onoue I, Kaneko K, Miyasaka N, Nanki T. Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis. J Pharmacol Exp Ther. 2012;340(1):109\u201313.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"534_CR131","doi-asserted-by":"publisher","first-page":"e78619","DOI":"10.1371\/journal.pone.0078619","volume":"8","author":"T Zhang","year":"2013","unstructured":"Zhang T, Bai X, Mao X. Systemic delivery of small interfering RNA targeting the interleukin-2\/15 receptor beta chain prevents disease progression in experimental arthritis. PLoS ONE. 2013;8(11):e78619.","journal-title":"PLoS ONE"},{"key":"534_CR132","doi-asserted-by":"publisher","first-page":"155835","DOI":"10.1016\/j.cyto.2022.155835","volume":"152","author":"Y-m Zhong","year":"2022","unstructured":"Zhong Y-m, Zhang L-l, Lu W-t. Shang Y-n, Zhou H-y: moxibustion regulates the polarization of macrophages through the IL-4\/STAT6 pathway in rheumatoid arthritis. Cytokine. 2022;152:155835.","journal-title":"Cytokine"},{"issue":"7","key":"534_CR133","doi-asserted-by":"publisher","first-page":"8824","DOI":"10.1021\/acsami.1c23429","volume":"14","author":"H Fang","year":"2022","unstructured":"Fang H, Sha Y, Yang L, Jiang J, Yin L, Li J, Li B, Klumperman B, Zhong Z, Meng F. Macrophage-targeted hydroxychloroquine nanotherapeutics for rheumatoid arthritis therapy. ACS Appl Mater Interfaces. 2022;14(7):8824\u201337.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"10","key":"534_CR134","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2217\/nnm.11.90","volume":"6","author":"RI Scheinman","year":"2011","unstructured":"Scheinman RI, Trivedi R, Vermillion S, Kompella UB. Functionalized STAT1 SiRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomed (Lond). 2011;6(10):1669\u201382.","journal-title":"Nanomed (Lond)"},{"issue":"1","key":"534_CR135","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-019-1912-0","volume":"21","author":"Y Hu","year":"2019","unstructured":"Hu Y, Wang B, Shen J, Low SA, Putt KS, Niessen HWM, Matteson EL, Murphy L, Ruppert C, Jansen G, et al. Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):143.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"534_CR136","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3390\/molecules24122265","volume":"24","author":"T Fischer","year":"2019","unstructured":"Fischer T, Riedl R. Inhibitory antibodies designed for matrix metalloproteinase modulation. Molecules. 2019;24(12):2265.","journal-title":"Molecules"},{"issue":"6","key":"534_CR137","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3109\/17453670903448257","volume":"80","author":"B Pasternak","year":"2009","unstructured":"Pasternak B, Aspenberg P. Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics. Acta Orthop. 2009;80(6):693\u2013703.","journal-title":"Acta Orthop"},{"issue":"7","key":"534_CR138","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/07853890701477546","volume":"39","author":"M Okroj","year":"2007","unstructured":"Okroj M, Heinegard D, Holmdahl R, Blom AM. Rheumatoid arthritis and the complement system. Ann Med. 2007;39(7):517\u201330.","journal-title":"Ann Med"},{"issue":"9","key":"534_CR139","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrrheum.2017.125","volume":"13","author":"LA Trouw","year":"2017","unstructured":"Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538\u201347.","journal-title":"Nat Rev Rheumatol"},{"issue":"9602","key":"534_CR140","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861\u201374.","journal-title":"Lancet"},{"issue":"3","key":"534_CR141","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.coph.2010.02.002","volume":"10","author":"AM Jacobi","year":"2010","unstructured":"Jacobi AM, Dorner T. Current aspects of anti-CD20 therapy in rheumatoid arthritis. Curr Opin Pharmacol. 2010;10(3):316\u201321.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"534_CR142","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679\u2013707.","journal-title":"Clin Ther"},{"issue":"1","key":"534_CR143","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13075-016-1152-5","volume":"18","author":"M Lavielle","year":"2016","unstructured":"Lavielle M, Mulleman D, Goupille P, Bahuaud C, Sung HC, Watier H, Thibault G. Repeated decrease of CD4\u2009+\u2009T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. Arthritis Res Ther. 2016;18(1):253.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"534_CR144","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","volume":"5","author":"TF Tedder","year":"2009","unstructured":"Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):572\u20137.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"534_CR145","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.1038\/srep06935","volume":"4","author":"YA Rim","year":"2014","unstructured":"Rim YA, Yi H, Kim Y, Park N, Jung H, Kim J, Jung SM, Park SH, Ju JH. Self in vivo production of a synthetic biological drug CTLA4Ig using a minicircle vector. Sci Rep. 2014;4(1):6935.","journal-title":"Sci Rep"},{"issue":"1","key":"534_CR146","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","volume":"20","author":"S Cole","year":"2018","unstructured":"Cole S, Walsh A, Yin X, Wechalekar MD, Smith MD, Proudman SM, Veale DJ, Fearon U, Pitzalis C, Humby F. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Therapy. 2018;20(1):85.","journal-title":"Arthritis Res Therapy"},{"key":"534_CR147","doi-asserted-by":"crossref","unstructured":"Ma Jj, Ying J, Wang Jy X, Tt X, Ht J, Ht X, Lw. Shang wj, Wang wq, Feng jy: CD38 drives progress of osteoarthritis by affecting cartilage homeostasis. Orthopaedic Surgery; 2022.","DOI":"10.1111\/os.13258"},{"issue":"1","key":"534_CR148","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s42003-022-03344-6","volume":"5","author":"S Nayar","year":"2022","unstructured":"Nayar S, Pontarini E, Campos J, Berardicurti O, Smith CG, Asam S, Gardner DH, Colafrancesco S, Lucchesi D, Coleby R, et al. Immunofibroblasts regulate LT\u03b13 expression in tertiary lymphoid structures in a pathway dependent on ICOS\/ICOSL interaction. Commun Biology. 2022;5(1):413.","journal-title":"Commun Biology"},{"issue":"2","key":"534_CR149","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cpt.2929","volume":"114","author":"L Abuqayyas","year":"2023","unstructured":"Abuqayyas L, Chen PW, Dos Santos MT, Parnes JR, Doshi S, Dutta S, Houk BE. Pharmacokinetics and pharmacokinetic\/pharmacodynamic properties of Rozibafusp alfa, a bispecific inhibitor of <\u2009scp\u2009>\u2009baff\u2009and <\u2009scp\u2009>\u2009icosl: analyses of phase I clinical trials. Clin Pharmacol Ther. 2023;114(2):371\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"534_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-03344-6","volume":"5","author":"S Nayar","year":"2022","unstructured":"Nayar S, Pontarini E, Campos J, Berardicurti O, Smith CG, Asam S, Gardner DH, Colafrancesco S, Lucchesi D, Coleby R. Immunofibroblasts regulate LT\u03b13 expression in tertiary lymphoid structures in a pathway dependent on ICOS\/ICOSL interaction. Commun Biology. 2022;5(1):1\u201313.","journal-title":"Commun Biology"},{"issue":"3","key":"534_CR151","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1016\/j.bbmt.2018.12.666","volume":"25","author":"SR Dillon","year":"2019","unstructured":"Dillon SR, Yang J, Lewis KE, Evans LS, Mudri S, Wu R, Swiderek KM, Peng SL. Alpn-101, a dual ICOS\/CD28 antagonist, demonstrates potent and Dose-Dependent suppression of graft vs. Host disease (GvHD) in a human\/nsg mouse xenograft model, with activity superior to CD28 or ICOS single pathway antagonists. Biol Blood Marrow Transplant. 2019;25(3):S290\u20131.","journal-title":"Biol Blood Marrow Transplant"},{"key":"534_CR152","unstructured":"Cheng LE, Amoura Z, Cheah B, Hiepe F, Sullivan BA, Zhou L, Arnold GE, Tsuji WH, Merrill JT, Chung JB. BRIEF REPORT study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis. 2018."},{"issue":"1","key":"534_CR153","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/41.1.53","volume":"41","author":"F Jamar","year":"2002","unstructured":"Jamar F, Houssiau FA, Devogelaer JP, Chapman PT, Haskard DO, Beaujean V, Beckers C, Manicourt DH, Peters AM. Scintigraphy using a technetium 99m-labelled anti-E-selectin fab fragment in rheumatoid arthritis. Rheumatology (Oxford). 2002;41(1):53\u201361.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"534_CR154","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1517\/17425247.5.9.1027","volume":"5","author":"IH Tarner","year":"2008","unstructured":"Tarner IH, M\u00fcller-Ladner U. Drug delivery systems for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv. 2008;5(9):1027\u201337.","journal-title":"Expert Opin Drug Deliv"},{"issue":"33","key":"534_CR155","doi-asserted-by":"publisher","first-page":"8632","DOI":"10.1016\/j.biomaterials.2012.08.005","volume":"33","author":"HF Zhou","year":"2012","unstructured":"Zhou HF, Yan H, Senpan A, Wickline SA, Pan D, Lanza GM, Pham CT. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile Fumagillin prodrug nanoparticles. Biomaterials. 2012;33(33):8632\u201340.","journal-title":"Biomaterials"},{"issue":"8","key":"534_CR156","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/ncprheum0559","volume":"3","author":"D Lainer-Carr","year":"2007","unstructured":"Lainer-Carr D, Brahn E. Angiogenesis Inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol. 2007;3(8):434\u201342.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"534_CR157","doi-asserted-by":"publisher","first-page":"154741","DOI":"10.1016\/j.phymed.2023.154741","volume":"114","author":"W Jiao","year":"2023","unstructured":"Jiao W, Xu J, Wu D, Yu J, Zhang M, Liu L, Chen G. Anti-proliferation and anti-migration effects of Yishen Tongbi Decoction in experimental rheumatoid arthritis by suppressing SLC3A2\/integrin \u03b23 signaling pathways. Phytomedicine. 2023;114:154741.","journal-title":"Phytomedicine"},{"issue":"6","key":"534_CR158","doi-asserted-by":"publisher","first-page":"R266","DOI":"10.1186\/ar4112","volume":"14","author":"L Fan","year":"2012","unstructured":"Fan L, Wang Q, Liu R, Zong M, He D, Zhang H, Ding Y, Ma J. Citrullinated fibronectin inhibits apoptosis and promotes the secretion of pro-inflammatory cytokines in fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther. 2012;14(6):R266.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"534_CR159","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jaut.2012.05.021","volume":"39","author":"M-C Boissier","year":"2012","unstructured":"Boissier M-C, Semerano L, Challal S, Saidenberg-Kermanac\u2019h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun. 2012;39(3):222\u20138.","journal-title":"J Autoimmun"},{"issue":"23","key":"534_CR160","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1021\/bi100363t","volume":"49","author":"B Knuckley","year":"2010","unstructured":"Knuckley B, Causey CP, Jones JE, Bhatia M, Dreyton CJ, Osborne TC, Takahara H, Thompson PR. Substrate specificity and kinetic studies of pads 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry. 2010;49(23):4852\u201363.","journal-title":"Biochemistry"},{"issue":"28","key":"534_CR161","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1016\/j.tetlet.2008.05.021","volume":"49","author":"CP Causey","year":"2008","unstructured":"Causey CP, Thompson PR. An improved synthesis of haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4). Tetrahedron Lett. 2008;49(28):4383\u20135.","journal-title":"Tetrahedron Lett"},{"issue":"1","key":"534_CR162","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1021\/cb200258q","volume":"7","author":"JE Jones","year":"2012","unstructured":"Jones JE, Slack JL, Fang P, Zhang X, Subramanian V, Causey CP, Coonrod SA, Guo M, Thompson PR. Synthesis and screening of a Haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem Biol. 2012;7(1):160\u20135.","journal-title":"ACS Chem Biol"},{"issue":"2","key":"534_CR163","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/cei.12932","volume":"188","author":"VC Willis","year":"2017","unstructured":"Willis VC, Banda NK, Cordova KN, Chandra PE, Robinson WH, Cooper DC, Lugo D, Mehta G, Taylor S, Tak PP, et al. Protein arginine deiminase 4 Inhibition is sufficient for the amelioration of collagen-induced arthritis. Clin Exp Immunol. 2017;188(2):263\u201374.","journal-title":"Clin Exp Immunol"},{"key":"534_CR164","doi-asserted-by":"publisher","first-page":"149668","DOI":"10.1016\/j.bbrc.2024.149668","volume":"704","author":"C-W Yang","year":"2024","unstructured":"Yang C-W, Hsu H-Y, Lee Y-Z, Lee S-J. Vitamin B12 inhibits peptidylarginine deiminases and ameliorates rheumatoid arthritis in CAIA mice. Biochem Biophys Res Commun. 2024;704:149668.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"534_CR165","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.drudis.2018.06.017","volume":"23","author":"T Kok","year":"2018","unstructured":"Kok T, Wasiel AA, Cool RH, Melgert BN, Poelarends GJ, Dekker FJ. Small-molecule inhibitors of macrophage migration inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders. Drug Discovery Today. 2018;23(11):1910\u20138.","journal-title":"Drug Discovery Today"},{"issue":"1","key":"534_CR166","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/0929866522666151026122347","volume":"23","author":"X Hao","year":"2016","unstructured":"Hao X, Zhu Y, Zheng C, Fu X, Feng J, Shen B, Wei J. A comparison of biological activity of B lymphocyte stimulator (BLyS) antagonist peptibodies and the Elucidation of possible BLyS binding sites. Protein Pept Lett. 2016;23(1):17\u201323.","journal-title":"Protein Pept Lett"},{"issue":"7","key":"534_CR167","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ddr.20472","volume":"72","author":"CH Ding","year":"2011","unstructured":"Ding CH, Li R, Xu JH, Cicuttini FM, Jones G. Belimumab therapy for systemic lupus erythematosus and potential treatment of rheumatoid arthritis. Drug Dev Res. 2011;72(7):623\u201333.","journal-title":"Drug Dev Res"},{"key":"534_CR168","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.3389\/fimmu.2018.02698","volume":"9","author":"C Kowalczyk-Quintas","year":"2018","unstructured":"Kowalczyk-Quintas C, Chevalley D, Willen L, Jandus C, Vigolo M, Schneider P. Inhibition of Membrane-Bound BAFF by the Anti-BAFF antibody Belimumab. Front Immunol. 2018;9:2698.","journal-title":"Front Immunol"},{"issue":"3\u20134","key":"534_CR169","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000505379","volume":"105","author":"A Sun","year":"2020","unstructured":"Sun A, Benet LZ. Late-Stage failures of monoclonal antibody drugs: A retrospective case study analysis. Pharmacology. 2020;105(3\u20134):145\u201363.","journal-title":"Pharmacology"},{"issue":"6","key":"534_CR170","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a blys\/april dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol. 2021;43(6):666\u201373.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"534_CR171","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Hisaki H. SAT0126 A PHASE 2 STUDY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO BIOLOGICS. In. BMJ Publishing Group Ltd; 2019.","DOI":"10.1136\/annrheumdis-2019-eular.1894"},{"issue":"4","key":"534_CR172","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/art.41555","volume":"73","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K. Efficacy and safety of E6011, an Anti-Fractalkine monoclonal antibody, in patients with active rheumatoid arthritis with inadequate response to methotrexate: results of a randomized, Double\u2010Blind, Placebo\u2010Controlled phase II study. Arthritis Rheumatol. 2021;73(4):587\u201395.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"534_CR173","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/14397595.2020.1868675","volume":"31","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, et al. A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. Mod Rheumatol. 2021;31(4):783\u20139.","journal-title":"Mod Rheumatol"},{"key":"534_CR174","doi-asserted-by":"publisher","first-page":"10157","DOI":"10.3389\/ti.2022.10157","volume":"35","author":"T Kanzawa","year":"2022","unstructured":"Kanzawa T, Tokita D, Saiga K, Yamakawa T, Ishigooka H, Fukuda H, Katsumata H, Miyairi S, Ishii R, Hirai T. Role of Fractalkine-CX3CR1 Axis in acute rejection of mouse heart allografts subjected to ischemia reperfusion injury. Transpl Int. 2022;35:10157.","journal-title":"Transpl Int"},{"issue":"8","key":"534_CR175","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/annrheumdis-2021-220202","volume":"80","author":"E Vallejo-Yag\u00fce","year":"2021","unstructured":"Vallejo-Yag\u00fce E, Keystone EC, Kandhasamy S, Micheroli R, Finckh A, Burden AM. Primary and secondary non-response: in need of operational definitions in observational studies. Ann Rheum Dis. 2021;80(8):961\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"534_CR176","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1002\/art.39189","volume":"67","author":"M Hudson","year":"2015","unstructured":"Hudson M, Baron M, Colmegna I, Bernatsky S, Klein Oros K, Pastinen T, Greenwood C. Novel approaches to discovery of biomarkers in rheumatoid arthritis: comment on the Article by Oswald et al. Arthritis Rheumatol. 2015;67(8):2276\u20137.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"534_CR177","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/br.2012.42","volume":"1","author":"X Ma","year":"2013","unstructured":"Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomedical Rep. 2013;1(2):177\u201384.","journal-title":"Biomedical Rep"},{"issue":"681","key":"534_CR178","doi-asserted-by":"publisher","first-page":"eabq4419","DOI":"10.1126\/scitranslmed.abq4419","volume":"15","author":"N Biesemann","year":"2023","unstructured":"Biesemann N, Margerie D, Asbrand C, Rehberg M, Savova V, Agueusop I, Klemmer D, Ding-Pfennigdorff D, Schwahn U, Dudek M, et al. Additive efficacy of a bispecific anti\u2013TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis. Sci Transl Med. 2023;15(681):eabq4419.","journal-title":"Sci Transl Med"},{"issue":"1","key":"534_CR179","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/antib4010048","volume":"4","author":"R Fischer","year":"2015","unstructured":"Fischer R, Kontermann RE, Maier O. Targeting sTNF\/TNFR1 signaling as a new therapeutic strategy. Antibodies. 2015;4(1):48\u201370.","journal-title":"Antibodies"},{"key":"534_CR180","doi-asserted-by":"crossref","unstructured":"Chipps BE, Peters SP. Biologic therapies of Immunologic diseases, an issue of immunology and allergy clinics of North america, E-Book. Volume 37. Elsevier Health Sciences; 2017.","DOI":"10.1016\/S0889-8561(17)30020-6"},{"issue":"12","key":"534_CR181","doi-asserted-by":"publisher","first-page":"e113465","DOI":"10.1371\/journal.pone.0113465","volume":"9","author":"P Durez","year":"2014","unstructured":"Durez P, Vandepapeliere P, Miranda P, Toncheva A, Berman A, Kehler T, Mociran E, Fautrel B, Mariette X, Dhellin O, et al. Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. PLoS ONE. 2014;9(12):e113465.","journal-title":"PLoS ONE"},{"issue":"6","key":"534_CR182","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40262-016-0462-8","volume":"56","author":"EB Lee","year":"2017","unstructured":"Lee EB, Daskalakis N, Xu C, Paccaly A, Miller B, Fleischmann R, Bodrug I, Kivitz A. Disease-Drug interaction of sarilumab and Simvastatin in patients with rheumatoid arthritis. Clin Pharmacokinet. 2017;56(6):607\u201315.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"534_CR183","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrrheum.2014.108","volume":"10","author":"S Onuora","year":"2014","unstructured":"Onuora S. Rheumatoid arthritis: can Tofacitinib be used as first-line monotherapy for RA? Nat Rev Rheumatol. 2014;10(8):443.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"534_CR184","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","volume":"74","author":"D Boyle","year":"2015","unstructured":"Boyle D, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal A, Wei N, Rosengren S. The JAK inhibitor Tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1311\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"534_CR185","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1002\/art.38717","volume":"66","author":"A Thiolat","year":"2014","unstructured":"Thiolat A, Biton J, Decker P, Semerano L, Boissier M, Pers Y, Jorgensen C, Plence L, Bessis N. Does Tocilizumab indeed reduce the frequency of Th17 cells?? Comment on the Article by thiolat et al. Arthritis Rheumatol. 2014;66(9):2640\u20131.","journal-title":"Arthritis Rheumatol"},{"key":"534_CR186","doi-asserted-by":"crossref","unstructured":"Guerra M, Ganh\u00e3o S, Martins-Rocha T, Ferreira R, Fernandes BM, Garcia S, Pimenta S, Bernardo A, Bernardes M, Costa L. AB0380IS THERE AN EFFECT OF TOCILIZUMAB IN SERUM AUTOANTIBODIES LEVELS IN RHEUMATOID ARTHRITIS? In. BMJ Publishing Group Ltd; 2019.","DOI":"10.1136\/annrheumdis-2019-eular.608"},{"key":"534_CR187","doi-asserted-by":"publisher","first-page":"104497","DOI":"10.1016\/j.phrs.2019.104497","volume":"150","author":"ST Law","year":"2019","unstructured":"Law ST, Taylor PC. Role of biological agents in treatment of rheumatoid arthritis. Pharmacol Res. 2019;150:104497.","journal-title":"Pharmacol Res"},{"issue":"10","key":"534_CR188","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s10067-019-04595-1","volume":"38","author":"Y Huang","year":"2019","unstructured":"Huang Y, Fan Y, Liu Y, Xie W, Zhang Z. Efficacy and safety of Secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials. Clin Rheumatol. 2019;38(10):2765\u201376.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"534_CR189","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","volume":"22","author":"B Combe","year":"2020","unstructured":"Combe B, Rahman P, Kameda H, Ca\u00f1ete JD, Gallo G, Agada N, Xu W, Genovese MC. Safety results of Ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Therapy. 2020;22(1):14.","journal-title":"Arthritis Res Therapy"},{"issue":"4","key":"534_CR190","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/cpdd.611","volume":"8","author":"AA Othman","year":"2019","unstructured":"Othman AA, Khatri A, Loebbert R, Peloso PM. Pharmacokinetics, safety, and tolerability of the dual inhibitor of tumor necrosis Factor-alpha and Interleukin 17A, ABBV-257, in healthy volunteers and patients with rheumatoid arthritis. Clin Pharmacol Drug Dev. 2019;8(4):492\u2013502.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"534_CR191","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013;72(9):1445\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"534_CR192","doi-asserted-by":"publisher","first-page":"280","DOI":"10.14412\/1995-4484-2018-280-285","volume":"56","author":"E Nasonov","year":"2018","unstructured":"Nasonov E, Stanislav M, Mazurov V, Chernykh T, Sorotskaya V, Salnikova T, Saikovsky R, Reshet\u2019ko O, Popova T, Shmidt E. Long-term safety and efficacy of Tocilizumab in patients with early rheumatoid arthritis of moderate or high activity (results of phase III multicenter extension clinical study ML28124). Rheumatol Sci Pract. 2018;56(3):280\u20135.","journal-title":"Rheumatol Sci Pract"},{"issue":"4","key":"534_CR193","first-page":"694","volume":"37","author":"EH Choy","year":"2019","unstructured":"Choy EH, Miceli-Richard C, Gonz\u00e1lez-Gay MA, Sinigaglia L, Schlichting DE, Meszaros G, de la Torre I, Schulze-Koops H. The effect of JAK1\/JAK2 Inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol. 2019;37(4):694\u2013670.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"534_CR194","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT, Scott LJ. Baricitinib: a review in rheumatoid arthritis. Drugs. 2018;78(7):761\u201372.","journal-title":"Drugs"},{"issue":"8","key":"534_CR195","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/13543784.2014.918604","volume":"23","author":"P Norman","year":"2014","unstructured":"Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067\u201377.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"534_CR196","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2217\/imt-2018-0178","volume":"11","author":"J Jegatheeswaran","year":"2019","unstructured":"Jegatheeswaran J, Turk M, Pope JE. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy. 2019;11(8):737\u201354.","journal-title":"Immunotherapy"},{"issue":"1","key":"534_CR197","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, Ortmann RA, Rocha G, Rooney TP, Wehrman T, et al. Comparison of baricitinib, upadacitinib, and Tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"534_CR198","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1517\/14712590903092188","volume":"9","author":"XT Lima","year":"2009","unstructured":"Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Expert Opin Biol Ther. 2009;9(8):1107\u201313.","journal-title":"Expert Opin Biol Ther"},{"key":"534_CR199","doi-asserted-by":"crossref","unstructured":"Ryan C, Leonardi CL. Ustekinumab. Advances in psoriasis. edn.: Springer; 2014. pp. 197\u2013207.","DOI":"10.1007\/978-1-4471-4432-8_15"},{"issue":"7","key":"534_CR200","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.4049\/jimmunol.167.7.3545","volume":"167","author":"L Dumoutier","year":"2001","unstructured":"Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol. 2001;167(7):3545\u20139.","journal-title":"J Immunol"},{"issue":"4","key":"534_CR201","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/icb.2014.102","volume":"93","author":"B Helling","year":"2015","unstructured":"Helling B, Konig M, Dalken B, Engling A, Kromer W, Heim K, Wallmeier H, Haas J, Wildemann B, Fritz B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015;93(4):396\u2013405.","journal-title":"Immunol Cell Biol"},{"issue":"101","key":"534_CR202","doi-asserted-by":"publisher","first-page":"101ra192","DOI":"10.1126\/scitranslmed.3002432","volume":"3","author":"K Owczarczyk","year":"2011","unstructured":"Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, Kelman A, Brunetta P, Lewin-Koh N, Sorani M, et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med. 2011;3(101):101ra192.","journal-title":"Sci Transl Med"},{"issue":"6","key":"534_CR203","doi-asserted-by":"publisher","first-page":"e0157961","DOI":"10.1371\/journal.pone.0157961","volume":"11","author":"E Quattrocchi","year":"2016","unstructured":"Quattrocchi E, Ostergaard M, Taylor PC, van Vollenhoven RF, Chu M, Mallett S, Perry H, Kurrasch R. Safety of repeated Open-Label treatment courses of intravenous ofatumumab, a human Anti-CD20 monoclonal antibody, in rheumatoid arthritis: results from three clinical trials. PLoS ONE. 2016;11(6):e0157961.","journal-title":"PLoS ONE"},{"issue":"2","key":"534_CR204","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrrheum.2013.168","volume":"10","author":"GR Burmester","year":"2014","unstructured":"Burmester GR, Feist E, D\u00f6rner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(2):77.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"534_CR205","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40265-018-0927-1","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A. Fostamatinib: first global approval. Drugs. 2018;78(9):959\u201363.","journal-title":"Drugs"},{"issue":"3","key":"534_CR206","first-page":"217","volume":"50","author":"M Chianelli","year":"2006","unstructured":"Chianelli M, D\u2019alessandria C, Conti F, Priori R, Valesini G, Annovazzi A, Signore A. New radiopharmaceuticals for imaging rheumatoid arthritis. Q J Nuclear Med Mol Imaging. 2006;50(3):217\u201325.","journal-title":"Q J Nuclear Med Mol Imaging"},{"issue":"1","key":"534_CR207","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrrheum.2012.176","volume":"9","author":"F Apparailly","year":"2013","unstructured":"Apparailly F, Jorgensen C. siRNA-based therapeutic approaches for rheumatic diseases. Nat Rev Rheumatol. 2013;9(1):56.","journal-title":"Nat Rev Rheumatol"},{"key":"534_CR208","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jconrel.2022.06.015","volume":"348","author":"T Siefen","year":"2022","unstructured":"Siefen T, Bjerregaard S, Borglin C, Lamprecht A. Assessment of joint pharmacokinetics and consequences for the intraarticular delivery of biologics. J Controlled Release. 2022;348:745\u201359.","journal-title":"J Controlled Release"},{"key":"534_CR209","doi-asserted-by":"crossref","unstructured":"Hossen N, Hye T, Ahsan F. Biopharmaceutics, pharmacokinetics, and pharmacodynamics of biological products. Biologics and biosimilars. edn.: CRC; 2022. pp. 121\u201336.","DOI":"10.1201\/9780429485626-9"},{"issue":"8","key":"534_CR210","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/pharmaceutics16081076","volume":"16","author":"R Deshmukh","year":"2024","unstructured":"Deshmukh R, Sethi P, Singh B, Shiekmydeen J, Salave S, Patel RJ, Ali N, Rashid S, Elossaily GM, Kumar A. Recent review on biological barriers and Host\u2013Material interfaces in precision drug delivery: advancement in biomaterial engineering for better treatment therapies. Pharmaceutics. 2024;16(8):1076.","journal-title":"Pharmaceutics"},{"issue":"11","key":"534_CR211","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-015-0296-9","volume":"54","author":"D Ternant","year":"2015","unstructured":"Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G. Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin Pharmacokinet. 2015;54(11):1107\u201323.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"534_CR212","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bcp.12509","volume":"79","author":"D Ternant","year":"2015","unstructured":"Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerre T, Le Loet X, Vittecoq O, Goupille P, Mulleman D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79(2):286\u201397.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"534_CR213","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","volume":"25","author":"MH Weisman","year":"2003","unstructured":"Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700\u201321.","journal-title":"Clin Ther"},{"issue":"7","key":"534_CR214","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45(7):792\u2013801.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"534_CR215","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/0091270010372520","volume":"51","author":"C Hu","year":"2011","unstructured":"Hu C, Xu Z, Zhang Y, Rahman MU, Davis HM, Zhou H. Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2011;51(5):639\u201348.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"534_CR216","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/0091270006298188","volume":"47","author":"H Zhou","year":"2007","unstructured":"Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47(3):383\u201396.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"534_CR217","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/bcp.12313","volume":"78","author":"D Ternant","year":"2014","unstructured":"Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V, Solau-Gervais E, Watier H, Goupille P, Paintaud G, et al. Relationship between inflammation and Infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol. 2014;78(1):118\u201328.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"534_CR218","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","volume":"2","author":"N Goel","year":"2010","unstructured":"Goel N, Stephens S. Certolizumab Pegol. mAbs. 2010;2(2):137\u201347.","journal-title":"mAbs"},{"issue":"1","key":"534_CR219","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jcph.185","volume":"54","author":"S Ohta","year":"2014","unstructured":"Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E, Ishida Y, Tarumi E, Imai M. Mechanism-based approach using a biomarker response to evaluate Tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol. 2014;54(1):109\u201319.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"534_CR220","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/0091270009350623","volume":"50","author":"N Frey","year":"2010","unstructured":"Frey N, Grange S, Woodworth T. Population Pharmacokinetic analysis of Tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50(7):754\u201366.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"534_CR221","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40262-019-00765-1","volume":"58","author":"C Xu","year":"2019","unstructured":"Xu C, Su Y, Paccaly A, Kanamaluru V. Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis. Clin Pharmacokinet. 2019;58(11):1455\u201367.","journal-title":"Clin Pharmacokinet"},{"key":"534_CR222","doi-asserted-by":"crossref","unstructured":"Dasegowda KR, Kavyasree MY, Prabhavathi H, Rambabu M, Vasudevan K, Kareem MA. Applications of Artificial Intelligence, Machine Learning, and Deep Learning in Diagnosis and Treatment of Rheumatoid Arthritis. In: Artificial Intelligence and Autoimmune Diseases: Applications in the Diagnosis, Prognosis, and Therapeutics. edn. Edited by Raza K, Singh S. Singapore: Springer Nature Singapore; 2024: 255\u2013268.","DOI":"10.1007\/978-981-99-9029-0_12"},{"issue":"1","key":"534_CR223","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/all.14494","volume":"76","author":"P Azzano","year":"2021","unstructured":"Azzano P, Dufresne \u00c9, Poder T, B\u00e9gin P. Economic considerations on the usage of biologics in the allergy clinic. Allergy. 2021;76(1):191\u2013209.","journal-title":"Allergy"},{"issue":"1","key":"534_CR224","doi-asserted-by":"publisher","first-page":"e002898","DOI":"10.1136\/rmdopen-2022-002898","volume":"9","author":"JTT C\u00e9leste","year":"2023","unstructured":"C\u00e9leste JTT, Van den Daniel B, Rieke A, Katerina A, James C, John G, Denis I, Verschueren M, Arnold P. Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open. 2023;9(1):e002898.","journal-title":"RMD Open"}],"container-title":["Journal of Biological Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-025-00534-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13036-025-00534-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-025-00534-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:34:36Z","timestamp":1757288076000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbioleng.biomedcentral.com\/articles\/10.1186\/s13036-025-00534-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":224,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1186\/s13036-025-00534-8","relation":{},"ISSN":["1754-1611"],"issn-type":[{"value":"1754-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}